Leukemia Research
Volume 26, Issue 10 , Pages 927-931 , October 2002

Free radical production and labile iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell lines

Received 9 October 2001 ,Accepted 9 February 2002.

References 

  1. Hortobagyi GN. Anthracyclines in the treatment of cancer. an overview. Drugs. 1997;54:1–7
  2. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999;57:727–741
  3. Papadopoulou LC, Tsiftsoglou AS. Mitochondrial cytochrome c oxidase as a target site for daunomycin in K-562 cells and heart tissue. Cancer Res. 1993;53:1072–1078
  4. Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res. 1983;43:4543–4551
  5. Powis G. Free radical formation by antitumor quinones. Free Radical Biol. Med. 1989;6:63–101
  6. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol. Ther. 1990;47:219–231
  7. Casazza AM. Anthracyclines as inducers of tumor cell differentiation. In: Lown JW, editor. Bioactive Molecules. Amsterdam: Elsevier, 1988. pp. 715–34.
  8. Jeannesson P, Lahlil R, Chénais B, Devy L, Gillet R, Aries A, et al.  Anthracyclines as tumor cell differentiating agents: effects on the regulation of erythroid gene expression. Leuk. Lymph. 1997;26:575–587
  9. Schwartz EL, Sartorelli AC. Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukaemia cells by anthracyclines. Cancer Res. 1982;42:2651–2655
  10. Ando S, Nakamura T, Kagawa D, Ueda T, Nishimura T, Kubo A, et al. Pharmacokinetics of aclarubicin and its metabolites in humans and their disposition in blood cells. Cancer Treat. Rep. 1986;70:835–841
  11. Nowak D, Drzewoski J. Anthracycline-induced oxidative stress: its role in the development of cardiac damage. Cancer J. 1996;9:296–303
  12. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997;11:931–936
  13. Chénais B, Andriollo M, Guiraud P, Belhoussine R, Jeannesson P. Oxidative stress involvement in chemically induced differentiation of K562 cells. Free Radical Biol. Med. 2000;28:18–27
  14. Halliwell B, Gutteridge JM. Biologically relevant metal ion-dependent hydroxyl radical generation, an update. FEBS Lett. 1992;307:108–112
  15. Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. 1996;127:272–278
  16. Minotti G, Cairo G, Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song. FASEB J. 1999;13:199–212
  17. Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik ZI. Fluorescence analysis of the labile iron pool of mammalian cells. Anal. Biochem. 1997;248:31–40
  18. Hentze MW, Kühn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide and oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 1996;93:8175–8182
  19. Picard V, Epsztejn S, Santambrogio P, Cabantchik ZI, Beaumont C. Role of ferritin in the control of the labile iron pool in murine erythroleukemia cells. J. Biol. Chem. 1998;273:15382–15386
  20. Picard V, Renaudie F, Porcher C, Hentze MW, Grandchamp B, Beaumont C. Overexpression of the ferritin H subunit in cultured erythroid cells changes the intracellular iron distribution. Blood. 1996;87:2057–2064
  21. Sinha BK, Trush MA, Kennedy KA, Minnaugh EG. Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res. 1984;44:2892–2896
  22. Pigeolet E, Corbisier P, Houbion A, Lambert D, Michiels C, Raes M, et al.  Glutathione peroxidase, superoxide dismutase, and catalase inactivation by peroxides and oxygen derived free radicals. Mech. Ageing Dev. 1990;51:283–297
  23. Julicher RH, Sterrenberg L, Bast A, Riksen RO, Koomen JM, Noordhoek J. The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart. J. Pharm. Pharmacol. 1986;38:277–282
  24. Sazuka Y, Tanizawa H, Takino Y. Effect of adriamycin on the activities of superoxide dismutase, glutathione peroxidase and catalase in tissues of mice. Jpn. J. Cancer Res. 1989;80:89–94
  25. Nagy K, Pasti G, Bene L, Zs-Nagy I. Induction of granulocytic maturation of HL-60 human leukemia cells by free radicals: a hypothesis of cell differentiation involving hydroxyl radicals. Free Radical Res. Comm. 1993;19:1–6
  26. Nagy K, Pasti G, Bene L, Zs-Nagy I. Involvement of Fenton reaction products in differentiation induction of K562 human leukemia cells. Leuk. Res. 1995;19:203–212
  27. Gazitt Y, Reddy SV, Alcantara O, Yang J, Boldt DH. A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myristate acetate. J. Cell Physiol. 2001;187:124–135
  28. Scaccabarozzi A, Arosio P, Weiss G, Valenti L, Dongiovanni P, Fracanzani AL, et al.  Relationship between TNF-alpha and iron metabolism in differentiating human monocytic THP-1 cells. Br. J. Haematol. 2000;110:978–984
  29. Gianni L, Zweier JL, Levy A, Myers CE. Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen. J. Biol. Chem. 1985;260:6820–6826
  30. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, et al.  The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J. 1998;12:541–552
  31. Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res. 2001;61:8422–8428
  32. Ngo-Nyoung M, Trentesaux C, Aries A, Carpentier Y, Jardillier J-C, Gorisse MC, et al.  Effect of aclacinomycin-doxorubicin association on differentiation and growth of human erythroleukemic K562 cells. Anticancer Res. 1994;14:1203–1208
  33. Bill CA, Garrett KC, Harrell R, Tofilon PJ. Enhancement of radiation-induced cell killing and DNA double-strand breaks in a human tumor cell line using nanomolar concentrations of aclacinomycin A. Radiat. Res. 1992;129:315–321
  34. Bill CA, Grochan BM, Vrdoljak E, Mendoza EA, Tofilon PJ. Decreased repair of radiation-induced DNA double-strand breaks with cellular differentiation. Radiat. Res. 1992;132:254–258
  35. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem. 1996;271:20291–20299
  36. Fukuchi K, Tomoyasu S, Tsuruoka N, Gomi K. Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett. 1994;350:139–142
  37. Haq RU, Wereley JP, Chitambar CR. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp. Hematol. 1995;23:428–432
  38. Leardi A, Caraglia M, Selleri C, Pepe S, Pizzi C, Notaro R, et al.  Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br. J. Haematol. 1998;102:746–752
  39. Papadopoulou LC, Tsiftsoglou AS. Effects of hemin on apoptosis, suppression of cytochrome c oxidase gene expression, and bone-marrow toxicity induced by doxorubicin (adriamycin). Biochem. Pharmacol. 1996;52:713–722

PII: S0145-2126(02)00030-9

Leukemia Research
Volume 26, Issue 10 , Pages 927-931 , October 2002

Article Tools

* Image Usage & Resolution